{"schema_version":"secwatch.filing_event.v1","accession":"0001641489-25-000013","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.277045+00:00","generated_at":"2026-05-24T10:14:59.413947+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"vTv Therapeutics FY2024 net loss $18.5M; clinical hold lifted, Phase 3 CATT1 to resume Q2 2025","bullets":["Clinical hold on cadisegliatin program lifted March 14, 2025; Phase 3 CATT1 T1D trial to resume Q2 2025 with protocol amendment shortening to 6 months.","FY2024 net loss attributable to shareholders $18.5M ($3.20/share) vs $20.3M ($9.71/share) in FY2023.","Cash $36.7M at Dec 31, 2024, up from $9.4M a year earlier, boosted by private placement and ATM offering.","Appointed Martin Lafontaine as Chief Commercial Officer; he brings over 25 years of diabetes commercial experience.","R&D expenses fell to $11.5M in FY2024 from $13.6M in FY2023, due to reduced cadisegliatin costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001641489-25-000013","json":"https://secwatch.observer/filing/0001641489-25-000013.json","markdown":"https://secwatch.observer/filing/0001641489-25-000013.md","text":"https://secwatch.observer/filing/0001641489-25-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000164148925000013/0001641489-25-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000164148925000013/vtvt-20250320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T10:14:59.413947+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}